Rhenman & Partners Asset Management Ab Ultragenyx Pharmaceutical Inc. Transaction History

Rhenman & Partners Asset Management Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$84.4 - $177.39 $5.19 Million - $10.9 Million	-61,500 Closed	0 $0
Q2 2020 Jul 16, 2020	SELL	$46.91 - $78.22 $329,495 - $549,417	-7,024 Reduced 10.25%	61,500 $4.81 Million
Q1 2020 Apr 16, 2020	BUY	$33.8 - $62.9 $2.32 Million - $4.31 Million	68,524 New	68,524 $3.05 Million
Q1 2018 Apr 11, 2018	SELL	$44.33 - $58.52 $4.21 Million - $5.56 Million	-95,000 Closed	0 $0
Q4 2017 Jan 19, 2018	SELL	$43.54 - $57.32 $217,700 - $286,600	-5,000 Reduced 5.0%	95,000 $4.41 Million

Q3 2017 Oct 13, 2017	BUY	$49.79 - $66.32 $4.98 Million - $6.63 Million	100,000	100,000 $5.33 Million

286

78.6M

570K

228K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.87B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.